Current Milestones & Catalysts
Post# of 30027
Posted On: 05/29/2014 9:53:48 AM
Amarantus 2014 Current Milestones & Catalysts
LymPro
• Pilot clinical performance data (1H-14);
• Retrospective / prognostic 9 year patient record clinical study (1H-14);
• Clinical Performance studies to support CLIA registration (1H-14);
• Commercial Launch as a Laboratory-Developed Test (“LDT”) under CLIA (2H- 2014);
Eltoprazine
• Evaluate best indication for commercial development (1H/14)
• Initiate Phase 2b Clinical Trial (1H/14)
MANF
• Retinitis Pigmentosa: functional genetic mouse model (1H-14)
• Parkinson’s disease: CED delivery data w/Renishaw (1H-14)
• Preliminary systemic toxicology (PK/PD relationship) (1H-14)
• Wolfram Syndrome enablement (Diabetes)
LymPro
• Pilot clinical performance data (1H-14);
• Retrospective / prognostic 9 year patient record clinical study (1H-14);
• Clinical Performance studies to support CLIA registration (1H-14);
• Commercial Launch as a Laboratory-Developed Test (“LDT”) under CLIA (2H- 2014);
Eltoprazine
• Evaluate best indication for commercial development (1H/14)
• Initiate Phase 2b Clinical Trial (1H/14)
MANF
• Retinitis Pigmentosa: functional genetic mouse model (1H-14)
• Parkinson’s disease: CED delivery data w/Renishaw (1H-14)
• Preliminary systemic toxicology (PK/PD relationship) (1H-14)
• Wolfram Syndrome enablement (Diabetes)
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼